Xiaobin Wu

Xiaobin Wu currently serves as the Global President and Chief Operating Officer at BeiGene, a position held since May 2018. Prior experience includes serving as Regional President for Essential Health in Greater China and President and Managing Director for China and Hong Kong at Pfizer from January 2004 to April 2018, following the acquisition of Wyeth Pharmaceuticals. Xiaobin Wu also held the role of General Manager for Bayer in China from January 2001 to January 2004. Educational qualifications include a Doctor of Philosophy (PhD) in Biochemistry and Pharmacology and a Master's degree in Molecular Biology, both from the University of Konstanz.